Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Hiroaki IkesueKohei DoiMayu MorimotoMasaki HirabatakeNobuyuki MuroiShinsuke YamamotoToshihiko TakenobuTohru HashidaPublished in: Cancer chemotherapy and pharmacology (2021)
Our results suggest that switching from ZA to denosumab significantly increases the risk for developing MRONJ in patients with bone metastases.